US Senate asks Novartis to shed light on data manipulation allegations
The one-time treatment for spinal muscular atrophy costs $2.1 million (CHF2.1 million).
Keystone / Yannick Bailly
The Swiss pharmaceutical firm Novartis has been asked to provide details regarding possible data inaccuracies for its human gene therapy Zolgensma – the world’s most expensive treatment.
Novartis has been accused of withholding information about manipulated data during early testing of Zolgensma, a one-time $2.1 million (CHF2.1 million) treatment for spinal muscular atrophy (SMA), the leading genetic cause of death in infants. The treatment was approved by the US Food and Drug Administration (FDA) in May.
Novartis said its subsidiary in California began investigating the alleged data manipulation for Zolgensma as soon as it learned about it. The company claims that it shared the information with the FDA as soon as it had the interim conclusions.
The chairman of the US Senate Finance Committee, Chuck Grassley, wants to have access to internal reports and to know exactly when the group became aware of the data manipulation. The Basel-based pharmaceutical giant has until August 23 to shed light on the situation. Novartis has acknowledged receipt of this request.
Despite the allegations, the FDA reported last week that it retains full confidence in the new treatment. However, it plans to take the case to court, as the pharmaceutical group was aware of the problem before receiving the green light to market it at the end of May.
“The agency will use its full authorities to take action, if appropriate, which may include civil or criminal penalties,” said an FDA statement last weekExternal link.
Novartis has blamed several employees of its subsidiary Avexis, but according to several analysts this case could cost it dearly. Zolgensma has yet to receive the green light from authorities in the European Union and Japan.
More
More
Novartis rejects suspected data manipulation in US
This content was published on
Swiss pharma giant Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to US authorities.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
This content was published on
The Swiss Broadcasting Corporation (SBC), Swissinfo's parent company, must restructure due to financial pressures and to stay competitive in the fast-moving media environment.
This content was published on
There has been a sharp decline in the consumption of single-use disposable plastic bags and reusable plastic bags in the Swiss retail sector.
This content was published on
A biometric Swiss identity card (ID) is expected to be available in Switzerland by the end of 2026. The Federal Office of Police and its federal and cantonal partners are working on a new ID card that features a chip.
Heatwave reduces output at Swiss nuclear power plant by 50%
This content was published on
The ongoing heatwave has forced the Beznau nuclear power plant, which relies on water from the River Aare, to halve its output.
Swiss continue to enjoy high social mobility, study shows
This content was published on
Opportunities for upward social mobility have remained intact in Switzerland since the 1980s. Social mobility is exceptionally high by international comparison, a study shows.
Swiss government affected by cyberattack on health foundation
This content was published on
Switzerland says a ransomware attack on the non-profit health foundation Radix that involved data being stolen and encrypted had also affected the federal administration.
Federal Council agrees to investigation into alleged Swiss-Russian spying affair
This content was published on
The Office of the Attorney General of Switzerland can open spying investigations into the Swiss Federal Intelligence Service (FIS).
Appeal launched against Starlink satellite antennae project planned in Swiss village
This content was published on
A group of Swiss citizens has filed an appeal against plans to install 40 Starlink satellite antennae in the mountain village of Leuk in southern Switzerland.
UBS launches buyback scheme for up to $2 billion in shares
This content was published on
UBS is starting a share buyback programme for up to $2 billion (CHF1.6 billion) in shares, in line with a plan approved at its annual general meeting (AGM) in April, the Swiss bank said on Monday.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
High pharma margins squeeze health systems
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
Push for drug pricing transparency strikes a nerve with industry
This content was published on
The 72nd World Health Assembly opens on Monday, but a draft resolution to end secrecy around drug pricing has already struck a nerve.
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.